Coherus BioSciences Inc (CHRS)

14h ago, source: Investing

Trevena, Inc. (NASDAQ:TRVN) announced that the FDA has accepted its new drug application seeking approval for intravenous (“IV”) oliceridine for management of ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript March 13, 2024 Coherus BioSciences, Inc. misses on ...

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

1mon ago, source: Business Insider

March 13, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2023 and ...

Coherus BioSciences Stock (NASDAQ:CHRS), Quotes and News Summary

1mon ago, source: Benzinga.com

Here Are 20 Stocks Moving Premarket Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ...

Coherus BioSciences: Q4 Earnings Snapshot

1mon ago, source: The Washington Post

REDWOOD CITY, Calif. — REDWOOD CITY, Calif. — Coherus BioSciences Inc. (CHRS) on Wednesday reported a loss of $79.7 million in its fourth quarter. The Redwood City, California-based company ...

Coherus BioSciences, Inc.: Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

10d ago, source:

In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion -- ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

We’re the only folks that have the three presentations. We’re positioned for market’s stability and sustainability as we go forward now with pegfilgrastim and that’s where we want to be ...

Coherus BioSciences, Inc.: Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

1mon ago, source: Finanznachrichten

March 13, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2023 and ...

Coherus BioSciences Inc CHRS

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Q4 2023 Coherus BioSciences Inc Earnings Call

1mon ago, source: Yahoo Finance

Jami Taylor; VP of IR; Coherus BioSciences, Inc. Dennis Lanfear; President and CEO; Coherus BioSciences, Inc. Paul Reider; Chief Commercial Officer; Coherus ...